JPRN-UMIN000008911已完成2 期
A randomized phase II study of TEC (Paclitaxel+Epirubicin+Carboplatin) therapy, TAC (Paclitaxel+Doxorubicin+Carboplatin)therapy, and ddTC (Dose-dense Paclitaxel+Carboplatin) therapy as adjuvant chemotherapy for the patients with intermediate or high risk group of endometrial carcinoma - ACE trial (GOGO-EM3 / Intergroup Study)
intergroup/GOGO0 个研究点目标入组 105 人开始时间: 2012年10月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 105
研究概览
简要总结
Compete rate of paclitaxel-epirubicin-carboplatin (TEC), paclitaxel-anthracycline (doxorubicin)-carboplatin (TAC), or dose-dense paclitaxel-carboplatin (ddTC) was 94%, 64%, and 69%, respectively (P = .005).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Patients with sarcomatous element 2)Active infections 3)Serious complications (heart disease, uncontrolled diabetes mellitus, malignant hypertension and tendency to bleeding) 4)Active concomitant malignancy 5)Interstitial pneumonitis and plumonary fibrosis 6)Massive pleural effusion or ascites 7)Neuropathy grade 2 or more (NCI-CTC) 8)Edema grade 2 or more (NCI-CTC) 9)prior chemotherapy including doxorubicin 10)Hypersensitivity to Polysorbate 80 or Cremophor EL 11) Pregnant or lactating women 12)Patients judged inappropriate for this study by the physicians
研究者
相似试验
已完成
2 期
Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 VariationsBreast CancerNCT02628613Fudan University91
已完成
3 期
A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)Breast CancerNCT00196872German Breast Group3,000
已完成
2 期
Paclitaxel and Epirubicin as neoadjuvant systemic treatment for locally advanced breast cancerCancer - BreastBreast cancerACTRN12611000307909The Queen Elizabeth Hospital40
Unknown
2 期
Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast CancerTriple Negative Breast CancerNCT01276769Chinese Academy of Medical Sciences80
已完成
2 期
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNCT00097227Eli Lilly and Company165